Simon S. Jones

发表

Isolation and characterization of genomic and cDNA clones of human erythropoietin

E. Fritsch, A. Mufson, C. Shoemaker, 1985, Nature.

Ricolinostat (ACY‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death

M. Selig, N. Raje, L. Boise, 2015, British journal of haematology.

Mechanistic Insights Into Fetal Hemoglobin (HbF) Induction Through Chemical Inhibition Of Histone Deacetylase 1 and 2 (HDAC1/2)

Simon S. Jones, John H. Van Duzer, Matthew Jarpe, 2013 .

Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability

B. Lee, J. Blendy, Ralph Mazitschek, 2014, Neuropsychopharmacology.

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.

P. Richardson, N. Raje, P. Voorhees, 2016, The Lancet. Oncology.

BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells.

Simon S. Jones, H. Dorai, S. Gould, 2002, Kidney international.

HDAC1,2 inhibition impairs EZH2- and BBAP- mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma

B. Cairns, J. Shearstone, J. Tyler, 2014, Oncotarget.

First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.

S. Cremers, Simon S. Jones, B. Shah, 2021, The oncologist.

Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor

Simon S. Jones, Brian J North, S. Quayle, 2017, PloS one.

A High-Throughput Method for Enzyme Kinetic Studies

Simon S. Jones, A. Adedoyin, D. Wei, 2003, Journal of biomolecular screening.

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

S. Jagannath, S. Lonial, P. Richardson, 2017, Clinical Cancer Research.

HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model

J. Pinilla-Ibarz, Simon S. Jones, S. Quayle, 2020, Frontiers in Immunology.

Synthesis of the 3'-terminal decaribonucleoside nonaphosphate of yeast alanine transfer ribonucleic acid

Simon S. Jones, B. Rayner, C. Reese, 1980 .

Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC

Simon S. Jones, A. Spencer, S. Mithraprabhu, 2013, British journal of haematology.

ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)

P. Richardson, N. Raje, N. Trede, 2015 .

Abstract 5380: Selective HDAC inhibition by ricolinostat (ACY-1215) or ACY-241 synergizes with IMiD® immunomodulatory drugs in Multiple Myeloma (MM) and Mantle Cell Lymphoma (MCL) cells

Simon S. Jones, S. Quayle, D. Tamang, 2015 .

Synthesis of the 3′-terminal half of yeast alanine transfer ribonucleic acid (tRNAAla) by the phosphotriester approach in solution. Part 1. Preparation of the nucleoside building blocks

Simon S. Jones, C. Christodoulou, Samson Sibanda, 1989 .

The protection of uracil and guanine residues in oligonucleotide synthesis

Simon S. Jones, Samson Sibanda, C. Reese, 1982 .

Migration of t-butyldimethylsilyl protecting groups

Simon S. Jones, C. Reese, 1979 .

STUDIES DIRECTED TOWARDS THE CHEMICAL SYNTHESIS OF YEAST ALANINE tRNA

Simon S. Jones, Samson Sibanda, C. Reese, 1983 .

(purple membrane/proton pump/oligonucleotide purification/site-sp4

H. Khorana, N. Hackett, Simon S. Jones, 2016 .

Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2

J. Shearstone, Apurva Chonkar, Simon S. Jones, 2016, PloS one.

The 2-(methylthiomethoxy)ethoxycarbonyl [mtmec] protecting group

Simon S. Jones, Samson Sibanda, C. Reese, 1981 .

Chemical synthesis of 5'-O-triphosphoryladenylyl-(2' .fwdarw. 5')-adenylyl-(2' .fwdarw. 5')-adenosine (2-5A)

Simon S. Jones, C. Reese, 1979 .

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma

S. Cremers, G. Bhagat, O. O’Connor, 2015, Clinical Cancer Research.

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

J. Bradner, S. Rodig, A. Kung, 2012, Blood.

Interleukin 4 is at 5q31 and interleukin 6 is at 7p15

M. F. Shannon, M. Vadas, G. Sutherland, 1988, Human Genetics.

A Novel Cytosolic Calcium-independent Phospholipase A2 Contains Eight Ankyrin Motifs*

R. Kriz, J. Seehra, Simon S. Jones, 1997, The Journal of Biological Chemistry.

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia

J. Shearstone, Pengyu Huang, Simon S. Jones, 2017, PloS one.

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.

Guocheng Yuan, P. Hammerman, Kwok-Kin Wong, 2017, Cancer discovery.

In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells

S. Grant, Simon S. Jones, S. Quayle, 2014, Molecular Cancer Therapeutics.

The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats

J. Sweeney, M. Ragozzino, Simon S. Jones, 2012, Psychopharmacology.

Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.

J. Pinilla-Ibarz, Simon S. Jones, E. Sotomayor, 2018, Blood advances.

Identity between the Ca2+-independent Phospholipase A2 Enzymes from P388D1 Macrophages and Chinese Hamster Ovary Cells*

J. Balsinde, M. Balboa, E. Dennis, 1997, The Journal of Biological Chemistry.

selective HDAC 6 inhibitor , ACY-1215 , in combination with bortezomib in Preclinical activity , pharmacodynamic and pharmacokinetic properties of a

J. Bradner, S. Rodig, A. Kung, 2012 .

Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models

Ralph Mazitschek, Pengyu Huang, Simon S. Jones, 2015, Oncotarget.

Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study

S. Jagannath, S. Lonial, P. Hari, 2012 .

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)

S. Jagannath, S. Lonial, P. Richardson, 2013 .

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)

S. Jagannath, S. Lonial, P. Richardson, 2015 .

Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)

S. Jagannath, S. Lonial, P. Richardson, 2014 .

Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)

J. Miguel, P. Richardson, N. Raje, 2016 .

Automating the Purification and Isolation of Synthetic DNA

E. Brown, Simon S. Jones, David K. Stone, 1987, Bio/Technology.

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

Kristina M. Ilieva, V. Petrenko, V. Sondak, 2014, Molecular Cancer Therapeutics.

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia

J. Shearstone, Pengyu Huang, Simon S. Jones, 2017, PloS one.

Role of Selective HDAC6 Inhibition On Multiple Myeloma Bone Disease

Bin Wang, R. Baron, M. Bouxsein, 2012 .